Exostar receives additional $10 million investment from Merck GHI

Commitment reflects impact of Exostar’s mission, vision, and solutions on life science and healthcare industries

Exostar has announced an additional $10 million investment in its life science and healthcare business from the Merck Global Health Innovation Fund (Merck GHI). Merck GHI’s investment will allow Exostar to enhance and expand its HIPAA-compliant solutions that help pharmaceutical companies, healthcare providers, and others in the industry securely, productively, and compliantly collaborate with one another to develop new drugs and therapies and deliver the best possible patient care. The latest round of funding follows a $5 million investment by Merck GHI in October 2014.

Richard Addi, President and Chief Executive Officer, Exostar, “We understand that data compromise can render that currency worthless, or worse. Life science and healthcare companies need a partner whose information security innovations and solutions not only protect scientific advances and patient information, but also enable organisations to accelerate how they do business. Exostar is that partner, and we are pleased Merck GHI has chosen once again to support us.”